A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Axitinib (Primary) ; Crizotinib (Primary)
- Indications Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 06 Jun 2017 Results (n=37; as of Aug 5, 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.
- 18 May 2017 Planned End Date changed from 13 Oct 2017 to 1 Oct 2017.